FDA Grants Approval for Brivaracetam ANDA219952 by Sciegen Pharmaceuticals
The FDA has granted approval for the Abbreviated New Drug Application (ANDA219952) for Brivaracetam submitted by Sciegen Pharmaceuticals.
Asset / Drug
Drug and asset intelligence for Brivaracetam with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.